Patents by Inventor Jiexian DONG

Jiexian DONG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-FGFR2 Antibody and Use Thereof
    Publication number: 20240101683
    Abstract: An anti-FGFR2 antibody, an encoding nucleic acid of the antibody, a vector and host cell for the expression and production thereof, an antibody-drug conjugate, and a pharmaceutical composition comprising the antibody. The present invention further relates to the use of the antibody molecule in a drug for diagnosing a cancer caused by FGFR2-pathway-related dysregulation, and the use of the antibody or antibody-drug conjugate in the preparation of a medicament for treating a cancer caused by FGFR2-pathway-related dysregulation, in particular gastric cancer.
    Type: Application
    Filed: December 29, 2021
    Publication date: March 28, 2024
    Inventors: Chenggang Zhu, Liangliang Xu, Jiexian Dong, Chaochun Zhang, Xuan Yang, Fangli Peng, Yeqing Li, Chaole Chen, Liming Bao, Xiangyan Min
  • NANOBODIES AGAINST CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) INHIBITORY FACTOR (Cif)
    Publication number: 20220169708
    Abstract: Provided are VHH or nanobodies that specifically bind to cystic fibrosis transmembrane conductance regulator (CFTR) inhibitory factor (Cif), and uses thereof for diagnosis and treatment of Pseudomonas infection.
    Type: Application
    Filed: December 7, 2021
    Publication date: June 2, 2022
    Inventors: Bruce D. HAMMOCK, Natalia VASYLIEVA, Jiexian DONG, Christophe MORISSEAU, Dean R. MADDEN
  • Nanobodies against cystic fibrosis transmembrane conductance regulator (CFTR) inhibitory factor (Cif)
    Patent number: 11225514
    Abstract: Provided are VHH or nanobodies that specifically bind to cystic fibrosis transmembrane conductance regulator (CFTR) inhibitory factor (Cif), and uses thereof for diagnosis and treatment of Pseudomonas infection.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: January 18, 2022
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Bruce D. Hammock, Natalia Vasylieva, Jiexian Dong, Christophe Morisseau, Dean R. Madden
  • NANOBODIES AGAINST CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) INHIBITORY FACTOR (Cif)
    Publication number: 20200231659
    Abstract: Provided are VHH or nanobodies that specifically bind to cystic fibrosis transmembrane conductance regulator (CFTR) inhibitory factor (Cif), and uses thereof for diagnosis and treatment of Pseudomonas infection.
    Type: Application
    Filed: May 29, 2018
    Publication date: July 23, 2020
    Inventors: Bruce D. HAMMOCK, Natalia VASYLIEVA, Jiexian DONG, Christophe MORISSEAU, Dean R. MADDEN